<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04471441</url>
  </required_header>
  <id_info>
    <org_study_id>B95-02LT1903</org_study_id>
    <nct_id>NCT04471441</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Everolimus Versus Mycophenolate Mofetil in Liver Transplant Recipients.</brief_title>
  <acronym>MONTBLANC</acronym>
  <official_title>Multi-center, Open-label, Randomized Controlled Phase 4 Study to Evaluate the Efficacy and Safety of CertiroBell® Compared With Mycophenolate Mofetil in Primary Living Donor Liver Transplant Recipients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of CertiroBell® tablet&#xD;
      compared with mycophenolate mofetil in primary living donor liver transplant recipients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is multi-center, open-label, randomized controlled phase 4 study to evaluate the&#xD;
      efficacy and safety of certirobell® tablet compared with mycophenolate mofetil in primary&#xD;
      living donor liver transplant recipients.&#xD;
&#xD;
      On the first visit the patients scheduled to be operated liver transplant in 35 days will be&#xD;
      conducted screening. Patients who meet the criteria of this clinical trial will be randomized&#xD;
      to CertiroBell or mycophenolate mofetil on the second visit. Each group will take CertiroBell&#xD;
      or mycophenolate mofetil and will conduct scheduled tests with 5 additional visits.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 30, 2020</start_date>
  <completion_date type="Anticipated">November 17, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 13, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of composite efficacy failure</measure>
    <time_frame>until 24 weeks after taking medicine</time_frame>
    <description>composite efficacy failure include biopsy-confirmed acute rejection, graft loss, death, or follow-up failure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of biopsy-confirmed acute rejection</measure>
    <time_frame>until 24weeks and 48weeks after taking medicine</time_frame>
    <description>acute rejection confirmed by result of biopsy(over 4 points of RAI score)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The pathological results and time of occurrence and method of treatment, result of the treatment of acute rejection confirmed by biopsy(over 4 points of RAI score)</measure>
    <time_frame>until 24weeks and 48weeks after taking medicine</time_frame>
    <description>details of acute rejection confirmed by result of biopsy(over 4 points of RAI score)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of composite efficacy failure</measure>
    <time_frame>until 48weeks after taking medicine</time_frame>
    <description>composite efficacy failure include biopsy-confirmed acute rejection, graft loss, death, or follow-up failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival rate of patients</measure>
    <time_frame>until 24weeks and 48weeks after taking medicine</time_frame>
    <description>Survival rate of patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival rate of transplanted organ</measure>
    <time_frame>until 24weeks and 48weeks after taking medicine</time_frame>
    <description>Survival rate of transplanted organ</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and recurrence rates of liver cancer</measure>
    <time_frame>until 24weeks and 48weeks after taking medicine</time_frame>
    <description>Incidence and recurrence rates of liver cancer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and recurrence rates of HCV infection</measure>
    <time_frame>until 24weeks and 48weeks after taking medicine</time_frame>
    <description>Incidence and recurrence rates of HCV infection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of CMV infection</measure>
    <time_frame>until 24weeks and 48weeks after taking medicine</time_frame>
    <description>Incidence of CMV infection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>variation of Serum creatinine, eGFR(estimated glomerular filtration rate) compared to the baseline</measure>
    <time_frame>at 24 weeks and 48weeks</time_frame>
    <description>eGFR using MDRD(Modification of Diet in Renal Disease) method</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Liver Transplant</condition>
  <arm_group>
    <arm_group_label>CertiroBell Tablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>De novo liver transplant recipients will be randomized after liver transplant operation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mycophenolate mofetil Tablet/Capsule</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>De novo liver transplant recipients will be randomized after liver transplant operation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus Tab.</intervention_name>
    <description>After first dose 1mg BID(total 2mg daily PO), check the blood concentration of everolimus at each visit and adjust the dose to acheive the blood concentration maintaining at 3~8ng/mL.</description>
    <arm_group_label>CertiroBell Tablet</arm_group_label>
    <other_name>CertiroBell Tab.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate mofetil Tab./Cap.</intervention_name>
    <description>Up to 1.5g BID(total 3g daily), PO</description>
    <arm_group_label>Mycophenolate mofetil Tablet/Capsule</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        * Inclusion Criteria:&#xD;
&#xD;
        [Time of screening]&#xD;
&#xD;
          -  Patients who have transplanted in primary living donor liver in 35 days or who plan to&#xD;
             be transplanted in primary living donor liver.&#xD;
&#xD;
          -  Over 20 years old(male or female)&#xD;
&#xD;
          -  Agreement with written informed consent&#xD;
&#xD;
        [Time of randomization] - Patients who have transplanted liver within 4 weeks(25 days to 35&#xD;
        days)&#xD;
&#xD;
        * Exclusion Criteria&#xD;
&#xD;
        [Time of screening]&#xD;
&#xD;
          -  Patients who have transplanted non-liver organs or have plan to be transplanted&#xD;
             non-liver organs.&#xD;
&#xD;
          -  Patients with bioartificial liver (cell system)&#xD;
&#xD;
          -  Patients who diagnosed with malignant tumor within 5 years [however, who have&#xD;
             recovered from skin cancer (squamous cell/basal cell carcinoma) or thyroid cancer,&#xD;
             hepatocellular carcinoma without main vessel invasion or extrahepatic metastasis can&#xD;
             be enrolled]&#xD;
&#xD;
          -  Patients with severe systemic infection&#xD;
&#xD;
          -  Women who are pregnant or breast feeding or not agree to the proper use of&#xD;
             contraception during the trial&#xD;
&#xD;
          -  Participated in other trial within 4 weeks&#xD;
&#xD;
          -  In investigator's judgement&#xD;
&#xD;
        [Time of randomization]&#xD;
&#xD;
          -  Patients with acute rejection who have been clinically treated after liver&#xD;
             transplantation.&#xD;
&#xD;
          -  Patients with complication related to the hepatic artery such as hepatic artery&#xD;
             thrombosis at the time of randomization.&#xD;
&#xD;
          -  At screening&#xD;
&#xD;
               -  WBC &lt;1,500/mm^3 or PLT &lt;30,000/mm^3 or over 3 times upper than normal range of&#xD;
                  liver function tests(T-bilirubin, AST, ALT) levels&#xD;
&#xD;
               -  Protein/Creatinine ratio(urine test) &gt; 1 or eGFR by MDRD&lt; 30mL/min/1.73m^2 or&#xD;
                  Total cholesterol &gt; 350mg/dL or triglycerides &gt; 500mg/dL&#xD;
&#xD;
          -  Patients taking HCV(hepatitis C virus) Therapeutic Drugs&#xD;
&#xD;
          -  Patients who had plasmapheresis within 1 week.&#xD;
&#xD;
          -  Patents who had a record of taking mTOR inhibitor before.&#xD;
&#xD;
          -  In investigator's judgement&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Soon Il Kim, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Severance Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Soon Il Kim, M.D., Ph.D.</last_name>
    <phone>82-2-2228-2131</phone>
    <email>SOONKIM@YUHS.AC</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Soo J Myung</last_name>
    <phone>82-2-6373-0658</phone>
    <email>sjm9@ckdpharm.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 10, 2020</study_first_submitted>
  <study_first_submitted_qc>July 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 15, 2020</study_first_posted>
  <last_update_submitted>July 10, 2020</last_update_submitted>
  <last_update_submitted_qc>July 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Everolimus</keyword>
  <keyword>CertiroBell</keyword>
  <keyword>Mycophenolate mofetil</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

